Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
about
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesCurrent trends in the treatment of primary mediastinal large B-cell lymphoma - an overviewNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewCatching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and ChangesDiffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Checkpoint inhibitors in hematological malignanciesPrimary mediastinal large B-cell lymphoma.Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyPD-L1 Status in Refractory Lymphomas.Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Targetable genetic features of primary testicular and primary central nervous system lymphomas.Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patientsRacial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis.PD-L1 Expression in Lung Cancer.Structural genomic alterations in primary mediastinal large B-cell lymphoma.Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Recurrent genomic rearrangements in primary testicular lymphoma.IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types.Genetic landscape and deregulated pathways in B-cell lymphoid malignancies.Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.The emerging role of immune checkpoint inhibition in malignant lymphoma.Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Targeting the programmed death-1 pathway in lymphoid neoplasms.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival iClinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeExpression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.
P2860
Q26748775-16AD3742-880E-4454-AE95-2E33B5C0871CQ26769596-CA2DC7F6-2819-4D0F-945C-0BEDBF2C359FQ27304386-14955D05-0918-436F-AD53-E99AF91AA614Q28076071-97E09503-ACC4-483A-8F17-8A586155315FQ28084351-80089754-C028-425C-A9B6-F5370F168FDCQ28087370-0C8B341D-E9D3-48CD-95C2-93A38617F946Q33622342-79A4B475-650C-41C3-9E7C-6C0D147C4DACQ33651495-965EEE44-586B-4773-AD78-73BBD91B0F5DQ34266819-E2939DDF-CAEC-42E5-8B37-9BA07773D413Q34802443-F7EF07D4-067D-49A7-BD48-13BE1AB988CEQ35850206-6EF81FA6-1CBB-48CC-BDE7-F5869D1F5FD8Q36043066-6F0C9D36-9877-4781-9573-09A85EA8C6F8Q36197517-4508F365-A5D2-45F7-96B7-3D65018C8B7BQ36253967-A2C56918-4BE5-4924-9B06-AD1B4256C092Q36522770-3C53CBDB-A4B9-4A76-A6A7-A07748F633ADQ36596879-2A53D12B-2685-4D22-AA17-AFD465AB877BQ37140496-B2652765-55BE-4B53-B5DD-4E294721E1CAQ37327973-69AD39D9-836E-4E9F-B1B3-056D6912F4EBQ37704352-A3388DED-6DAE-42B5-87F0-019C913ED69FQ38267888-D3951E13-1FF9-495B-910A-AD1DF8F029F0Q38294626-25370C12-673A-4871-9717-6D1C0C504628Q38387704-B9BCDAF5-388E-48B1-82C9-90DDC6DA5369Q38523971-CFA6E92F-6116-45F6-8766-A7F551684084Q38669131-4A3D5B0B-A4DE-402D-9F6D-193B8C6D0793Q38765494-D20865FF-2542-4259-971B-96CF3D4F4BF6Q38791036-F1E05818-97D1-4CB4-BDE7-4FA42CEA8A1DQ38793719-0102B791-043B-4EF9-9AD9-DE99DCAA210FQ38831655-D0F3C2A8-08A3-4A8B-BF01-D776995E18A4Q38839124-11E81F48-BADE-4161-820B-363FAF69E9F9Q38844205-18D4EB11-A29C-4A7F-A9C2-35B2B03DC985Q38847636-963A9521-5BB2-49CD-A721-855A808EE680Q38889427-3299D417-5379-4015-B67D-14F07733027FQ38988078-555F57E7-844F-4F8B-8549-9431CB4FBF52Q38996724-A2FB0D62-E63B-42C9-A01D-D0F0F6B50CB5Q39153358-C2F607DE-1602-45EF-A060-FB07B6CE71C1Q39237785-487452B1-FB5B-4EB1-A99B-08A5049CBEF5Q40415214-6D62BB5F-23AB-4157-B583-6BFADA182ECEQ40971062-312895CB-F478-48A2-B34B-46C34DAB89D1Q41069147-0B30670D-771D-4830-B594-A7A83924E278Q41356776-8EA0F883-DB8F-417E-AF69-A3083F3733B2
P2860
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@ast
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@en
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@nl
type
label
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@ast
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@en
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@nl
prefLabel
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@ast
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@en
Genomic rearrangements involvi ...... astinal large B-cell lymphoma.
@nl
P2093
P50
P1433
P1476
Genomic rearrangements involvi ...... iastinal large B-cell lymphoma
@en
P2093
Adele Telenius
Andrew W McPherson
Anja Mottok
Bruce W Woolcock
Christian Steidl
David D W Twa
David W Scott
Fong Chun Chan
Graham W Slack
Kerry J Savage
P304
P356
10.1182/BLOOD-2013-10-535443
P407
P577
2014-02-04T00:00:00Z